Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of “Moderate Buy” from Analysts
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
SG Americas Securities LLC Takes Position in Cogent Biosciences, Inc. $COGT
Market Today: Intel tumbles, TikTok JV, gas spikes, Netflix--WBD
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT
Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day.
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Squarepoint Ops LLC Purchases Shares of 101,518 Cogent Biosciences, Inc. $COGT
Assenagon Asset Management S.A. Purchases 380,345 Shares of Cogent Biosciences, Inc. $COGT
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
Cogent: Another Win For Bezuclastinib In GIST Warrants Continued Strong Buy
Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript